Effect of food on the pharmacokinetics of omeprazole, pantoprazole and rabeprazole
Open Access
- 25 July 2020
- journal article
- research article
- Published by Springer Nature in BMC Pharmacology and Toxicology
- Vol. 21 (1) , 1-9
Abstract
Background: The pharmacokinetics of proton pump inhibitors (PPIs) may be affected by food intake. We aimed to evaluate the effect of food on the pharmacokinetics of omeprazole, rabeprazole, and pantoprazole. Setting: The study population comprised 186 healthy volunteers participating in 6 bioequivalence clinical trials. Method: Subjects were evaluated to determine the effect of a high-fat breakfast on the pharmacokinetics of omeprazole (n = 36), rabeprazole (n = 69), and pantoprazole (n = 81). Main outcome measure: Drug plasma concentrations were measured using high-performance liquid chromatography coupled to mass spectrometry. Results: Food affected the pharmacokinetics of omeprazole (increased Tmax and decreased AUC and Cmax), pantoprazole (increased Tmax and decreased AUC), and rabeprazole (increased Tmax, Cmax and half-life). Food increased variability in Tmax for all 3 drugs, delaying absorption around 3 to 4 h and until 20 h in some subjects. Conclusion: As food delays the absorption of PPIs and increases their variability, it would be better to administer these drugs under fasting conditions. Trial registration: European Union Drug Regulating Authorities Clinical Trials Database: EudraCT: 2004–003863-59 (registration date 05/MAR/2004), EudraCT 2006–001162-17 (registration date 17-MAR-2006), EudraCT: 2007–002489-37 (registration date 12-JUN-2007), EudraCT: 2007–002490-31 (registration date 12-JUN-2007), EudraCT: 2010–024029-19 (registration date 23-NOV-2010).Keywords
Funding Information
- Fundación Teófilo Hernando
This publication has 20 references indexed in Scilit:
- Pharmacokinetics of a New Immediate-release Compound Omeprazole Capsule and its Comparison with the Enteric-coated Formulation under Fasting and Fed ConditionsDrug Research, 2013
- Pre-dinner administration increases the efficacy of proton pump inhibitors on refractory GERD symptoms in connective tissue disease patientsModern Rheumatology, 2012
- Novel Approaches to Inhibition of Gastric Acid SecretionCurrent Gastroenterology Reports, 2010
- Effect of timing of dosing in relation to food intake on the pharmacokinetics of esomeprazoleBritish Journal of Clinical Pharmacology, 2007
- Comparison of the effects of fasting morning, fasting evening and fed bedtime administration of tenatoprazole on intragastric pH in healthy volunteers: a randomized three‐way crossover studyAlimentary Pharmacology & Therapeutics, 2006
- The effect of the area under the plasma concentration vs time curve and the maximum plasma concentration of esomeprazole on intragastric pHEuropean Journal of Clinical Pharmacology, 2002
- Lack of a pharmacokinetic interaction between lansoprazole or pantoprazole and theophyllineAlimentary Pharmacology & Therapeutics, 2000
- MEDICAL THERAPYGastroenterology Clinics of North America, 1999
- Review article: the pharmacokinetics of rabeprazole in health and diseaseAlimentary Pharmacology & Therapeutics, 1999
- Effect of omeprazole--a gastric proton pump inhibitor--on pentagastrin stimulated acid secretion in man.Gut, 1983